Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 6/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | ALPL | P05186 | 1/20 | 0.68 |
| ▸ | ALPI | P09923 | 1/20 | 0.68 |
| ▸ | ALPG | P10696 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361922 | 0.94 | GAA (0.77) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL18136526 | 0.92 | HDAC1 (0.65) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL13381471 | 0.92 | ALDH1A1 (0.70) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL22341320 | 0.92 | FTO (0.67) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL18136525 | 0.91 | KMT2A (0.63) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL1019295 | 0.88 | HDAC1 (0.65) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL2988299 | 0.88 | HDAC1 (0.65) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL13381489 | 0.88 | KMT2A (0.68) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL5218533 | 0.88 | GAA (0.70) | HDAC1HDAC6KMT2AFTOGAA | |
| SCHEMBL255625 | 0.88 | CA1 (0.65) | HDAC1HDAC6KMT2AFTOGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | claimed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | claimed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| EP-1222171-B1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2004-02-25 | — | — | EP | disclosed |
| US-6624178-B2 | Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-09-23 | — | — | US | disclosed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | disclosed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | disclosed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | disclosed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| EP-1222171-A1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Torrent Pharmaceuticals Ltd (IN) | 2002-07-17 | — | — | EP | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
| WO-2001025208-A1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANKARANARAYANAN ALANGUDI (IN) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | HDAC1 1552/4885HDAC6 3417/4885KMT2A 4629/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | HDAC1 2199/4885HDAC6 4143/4885KMT2A 4457/4885 |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | HMOX1, HMOX2, PPOX | HDAC1 2442/4885HDAC6 3213/4885KMT2A 3310/4885 |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | HDAC1 1962/4885HDAC6 2348/4885KMT2A 3588/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | HDAC1 2175/4885HDAC6 2632/4885KMT2A 3459/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | HDAC1 2212/4885HDAC6 2340/4885KMT2A 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.